Determinants of costs and benefits in atopic dermatitis routine care in Germany
Open Access
- 18 May 2022
- journal article
- research article
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 36 (9) , 1450-1455
Abstract
Background and objectives: The economic burden of atopic dermatitis (AD) is of particular interest. The present study aims to analyse the association of disease‐related characteristics, annual costs and treatment benefits in AD.Methods: Between August 2017 and June 2019, a cross‐sectional observational study in patients with AD was conducted in Germany. Cost‐of‐illness data were assessed from the societal perspective. Disease characteristics included severity, time since diagnosis and therapy, as well as atopic comorbidity and the implementation of prevention measures. Subgroup analyses of the total costs were conducted for these characteristics. A linear regression model was applied to analyse the impact of disease characteristics on the costs. Furthermore, associations of biologic treatment with outcome parameters were analysed.Results: A total of 1291 patients from 111 centres were included in the analyses. The total costs amounted on average to € 3660 ± € 6428 per patient and year. Higher costs were shown in various patient groups, for example, in patients using biologics (€ 20 983 vs. € 2470). In a regression analysis, gender, education and the number of implemented prevention measures were identified as significant predictors of costs. Patients treated with biologics showed consistently better outcome parameters and were more often satisfied with their treatment.Conclusions: Gender, education and implemented prevention measures are significant cost determinants in AD. The results confirm that treatment with biologics is the main cost driver in AD. However, incremental patient‐relevant benefits of high‐priced therapy are reflected by the significantly better clinical outcomes in the group treated with biologics.Keywords
Funding Information
- Sanofi
This publication has 21 references indexed in Scilit:
- Atopic Dermatitis in US Adults: From Population to Health Care UtilizationThe Journal of Allergy and Clinical Immunology: In Practice, 2019
- Epidemiology of adult atopic dermatitisClinics in Dermatology, 2018
- Consensus‐based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part IIJournal of the European Academy of Dermatology and Venereology, 2018
- Measurement of healthcare quality in atopic dermatitis – development and application of a set of quality indicatorsJournal of the European Academy of Dermatology and Venereology, 2018
- Consensus‐based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part IJournal of the European Academy of Dermatology and Venereology, 2018
- Epidemiology of atopic dermatitis in adults: Results from an international surveyAllergy, 2018
- Effects of structured patient education in adults with atopic dermatitis: Multicenter randomized controlled trialJournal of Allergy and Clinical Immunology, 2017
- Prevalence and comorbidities in adults with psoriasis compared to atopic eczemaJournal of the European Academy of Dermatology and Venereology, 2016
- Atopic Dermatitis: Global Epidemiology and Risk FactorsAnnals of Nutrition and Metabolism, 2015
- The patient benefit index: a novel approach in patient-defined outcomes measurement for skin diseasesArchives of Dermatological Research, 2009